Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis
dc.contributor.author
Hooijmans, Carlijn R.
dc.contributor.author
Hlavica, Martin
dc.contributor.author
Schuler, Florian A.F.
dc.contributor.author
Good, Nicolas
dc.contributor.author
Good, Andrin
dc.contributor.author
Baumgartner, Lisa
dc.contributor.author
Galeno, Gianluca
dc.contributor.author
Schneider, Marc P.
dc.contributor.author
Jung, Tarzis
dc.contributor.author
De Vries, Rob
dc.contributor.author
Ineichen, Benjamin V.
dc.date.accessioned
2019-02-08T09:33:07Z
dc.date.available
2019-02-07T04:27:37Z
dc.date.available
2019-02-08T09:33:07Z
dc.date.issued
2019
dc.identifier.issn
2045-2322
dc.identifier.other
10.1038/s41598-018-35734-4
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/323482
dc.identifier.doi
10.3929/ethz-b-000323482
dc.description.abstract
An unmet but urgent medical need is the development of myelin repair promoting therapies for Multiple Sclerosis (MS). Many such therapies have been pre-clinically tested using different models of toxic demyelination such as cuprizone, ethidium bromide, or lysolecithin and some of the therapies already entered clinical trials. However, keeping track on all these possible new therapies and their efficacy has become difficult with the increasing number of studies. In this study, we aimed at summarizing the current evidence on such therapies through a systematic review and at providing an estimate of the effects of tested interventions by a meta-analysis. We show that 88 different therapies have been pre-clinically tested for remyelination. 25 of them (28%) entered clinical trials. Our meta-analysis also identifies 16 promising therapies which did not enter a clinical trial for MS so far, among them Pigment epithelium-derived factor, Plateled derived growth factor, and Tocopherol derivate TFA-12.We also show that failure in bench to bedside translation from certain therapies may in part be attributable to poor study quality. By addressing these problems, clinical translation might be smoother and possibly animal numbers could be reduced.
en_US
dc.format
application/pdf
en_US
dc.language.iso
en
en_US
dc.publisher
Nature
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.title
Remyelination promoting therapies in multiple sclerosis animal models: a systematic review and meta-analysis
en_US
dc.type
Journal Article
dc.rights.license
Creative Commons Attribution 4.0 International
dc.date.published
2019-01-29
ethz.journal.title
Scientific Reports
ethz.journal.volume
9
en_US
ethz.journal.issue
1
en_US
ethz.journal.abbreviated
Sci Rep
ethz.pages.start
822
en_US
ethz.size
17 p.
en_US
ethz.version.deposit
publishedVersion
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
London
ethz.publication.status
published
en_US
ethz.date.deposited
2019-02-07T04:27:39Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Open access
en_US
ethz.rosetta.installDate
2019-02-08T09:33:29Z
ethz.rosetta.lastUpdated
2024-02-02T07:08:13Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Remyelination%20promoting%20therapies%20in%20multiple%20sclerosis%20animal%20models:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Scientific%20Reports&rft.date=2019&rft.volume=9&rft.issue=1&rft.spage=822&rft.issn=2045-2322&rft.au=Hooijmans,%20Carlijn%20R.&Hlavica,%20Martin&Schuler,%20Florian%20A.F.&Good,%20Nicolas&Good,%20Andrin&rft.genre=article&rft_id=info:doi/10.1038/s41598-018-35734-4&
Files in this item
Publication type
-
Journal Article [131350]